Despite advances in detection, over 20% of CRC patients are diagnosed at the metastatic stage, which complicates treatment with chemotherapy and targeted therapies, such as those targeting vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) [2, 3]. This evidence concerns the gene VEGFA and colorectal carcinoma.